253 related articles for article (PubMed ID: 31504399)
1. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
de Vries TI; Eikelboom JW; Bosch J; Westerink J; Dorresteijn JAN; Alings M; Dyal L; Berkowitz SD; van der Graaf Y; Fox KAA; Visseren FLJ
Eur Heart J; 2019 Dec; 40(46):3771-3778a. PubMed ID: 31504399
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS; Widimsky P; Hori M; Avezum A; Piegas LS; Branch KRH; Probstfield J; Bhatt DL; Zhu J; Liang Y; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Kakkar AK; Fox KAA; Parkhomenko AN; Ertl G; Störk S; Keltai M; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim JH; Tonkin AM; Lewis BS; Felix C; Yusoff K; Steg PG; Metsarinne KP; Cook Bruns N; Misselwitz F; Chen E; Leong D; Yusuf S;
N Engl J Med; 2017 Oct; 377(14):1319-1330. PubMed ID: 28844192
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
[TBL] [Abstract][Full Text] [Related]
7. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Coppens M; Weitz JI; Eikelboom JWA
Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Fox KAA; Eikelboom JW; Shestakovska O; Connolly SJ; Metsarinne KP; Yusuf S
J Am Coll Cardiol; 2019 May; 73(18):2243-2250. PubMed ID: 31072566
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
[TBL] [Abstract][Full Text] [Related]
11. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
Lee MC; Liao CT; Toh HS; Chou CC; Chang WT; Chen ZC; Wu WS; Yu T; Strong C
Cardiovasc Drugs Ther; 2021 Jun; 35(3):539-547. PubMed ID: 32910340
[TBL] [Abstract][Full Text] [Related]
13. Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Darmon A; Sorbets E; Ducrocq G; Elbez Y; Abtan J; Popovic B; Ohman EM; Röther J; Wilson PF; Montalescot G; Zeymer U; Bhatt DL; Steg PG;
J Am Coll Cardiol; 2019 Jul; 73(25):3281-3291. PubMed ID: 31248549
[TBL] [Abstract][Full Text] [Related]
14. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
Bhatt DL; Eikelboom JW; Connolly SJ; Steg PG; Anand SS; Verma S; Branch KRH; Probstfield J; Bosch J; Shestakovska O; Szarek M; Maggioni AP; Widimský P; Avezum A; Diaz R; Lewis BS; Berkowitz SD; Fox KAA; Ryden L; Yusuf S;
Circulation; 2020 Jun; 141(23):1841-1854. PubMed ID: 32223318
[TBL] [Abstract][Full Text] [Related]
15. Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review.
Shanker A; Bhupathi V
Curr Cardiol Rep; 2019 May; 21(7):56. PubMed ID: 31104152
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial.
Anand SS; Eikelboom JW; Dyal L; Bosch J; Neumann C; Widimsky P; Avezum AA; Probstfield J; Cook Bruns N; Fox KAA; Bhatt DL; Connolly SJ; Yusuf S;
J Am Coll Cardiol; 2019 Jul; 73(25):3271-3280. PubMed ID: 31248548
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
Tsilimigras DI; Moris D; Karaolanis G; Kakkos SK; Filis K; Sigala F
Curr Pharm Des; 2018; 24(38):4516-4517. PubMed ID: 30621559
[TBL] [Abstract][Full Text] [Related]
18. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Nicholls SJ; Nelson AJ
Am J Cardiovasc Drugs; 2019 Aug; 19(4):343-348. PubMed ID: 30680652
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Darmon A; Elbez Y; Bhatt DL; Abtan J; Mas JL; Cacoub P; Montalescot G; Billaut-Laden I; Ducrocq G; Steg PG
Ann Cardiol Angeiol (Paris); 2020 Oct; 69(4):158-166. PubMed ID: 32778388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
